Listed

Immunome Inc.

IMNMNasdaqCIK 1472012HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q2 FY2026
Operating income−$78.1m, Q2 FY2026
Net income−$73.1m, Q2 FY2026
Immunome Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m3.6Revenue, Q3 FY2023, three months to 2023-09-30$3.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure3.8Revenue, Q4 FY2023, three months to 2023-12-31$3.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-19, accession 0001558370-25-003302. Derived: 12-month figure less the 9-month figure.Report this figure1.0Revenue, Q1 FY2024, three months to 2024-03-31$1.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure2.4Revenue, Q2 FY2024, three months to 2024-06-30$2.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure2.9Revenue, Q3 FY2024, three months to 2024-09-30$2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure2.7Revenue, Q4 FY2024, three months to 2024-12-31$2.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure2.9Revenue, Q1 FY2025, three months to 2025-03-31$2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure4.0Revenue, Q2 FY2025, three months to 2025-06-30$4.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Research and development$m3.8Research and development, Q3 FY2023, three months to 2023-09-30$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure9.6Research and development, Q4 FY2023, three months to 2023-12-31$9.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-19, accession 0001558370-25-003302. Derived: 12-month figure less the 9-month figure.Report this figure15.4Research and development, Q1 FY2024, three months to 2024-03-31$15.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure29.1Research and development, Q2 FY2024, three months to 2024-06-30$29.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure37.2Research and development, Q3 FY2024, three months to 2024-09-30$37.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure47.9Research and development, Q4 FY2024, three months to 2024-12-31$47.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure36.9Research and development, Q1 FY2025, three months to 2025-03-31$36.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure40.5Research and development, Q2 FY2025, three months to 2025-06-30$40.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure49.2Research and development, Q3 FY2025, three months to 2025-09-30$49.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure50.8Research and development, Q4 FY2025, three months to 2025-12-31$50.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure46.4Research and development, Q1 FY2026, three months to 2026-03-31$46.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure59.9Research and development, Q2 FY2026, three months to 2026-06-30$59.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Operating income$m(4.6)Operating income, Q3 FY2023, three months to 2023-09-30−$4.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure(94.7)Operating income, Q4 FY2023, three months to 2023-12-31−$94.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-19, accession 0001558370-25-003302. Derived: 12-month figure less the 9-month figure.Report this figure(132)Operating income, Q1 FY2024, three months to 2024-03-31−$132.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure(40.0)Operating income, Q2 FY2024, three months to 2024-06-30−$40.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure(50.5)Operating income, Q3 FY2024, three months to 2024-09-30−$50.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure(83.0)Operating income, Q4 FY2024, three months to 2024-12-31−$83.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure(44.6)Operating income, Q1 FY2025, three months to 2025-03-31−$44.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(46.5)Operating income, Q2 FY2025, three months to 2025-06-30−$46.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure(60.1)Operating income, Q3 FY2025, three months to 2025-09-30−$60.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure(72.9)Operating income, Q4 FY2025, three months to 2025-12-31−$72.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure(59.3)Operating income, Q1 FY2026, three months to 2026-03-31−$59.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(78.1)Operating income, Q2 FY2026, three months to 2026-06-30−$78.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Net income$m(4.3)Net income, Q3 FY2023, three months to 2023-09-30−$4.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure(92.6)Net income, Q4 FY2023, three months to 2023-12-31−$92.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-19, accession 0001558370-25-003302. Derived: 12-month figure less the 9-month figure.Report this figure(129)Net income, Q1 FY2024, three months to 2024-03-31−$129.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure(36.1)Net income, Q2 FY2024, three months to 2024-06-30−$36.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure(47.1)Net income, Q3 FY2024, three months to 2024-09-30−$47.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure(80.2)Net income, Q4 FY2024, three months to 2024-12-31−$80.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure(41.6)Net income, Q1 FY2025, three months to 2025-03-31−$41.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure(43.4)Net income, Q2 FY2025, three months to 2025-06-30−$43.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure(57.5)Net income, Q3 FY2025, three months to 2025-09-30−$57.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure(69.9)Net income, Q4 FY2025, three months to 2025-12-31−$69.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure(53.8)Net income, Q1 FY2026, three months to 2026-03-31−$53.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure(73.1)Net income, Q2 FY2026, three months to 2026-06-30−$73.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Diluted EPS$ per share(0.36)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figurenot reported(2.51)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$2.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure(0.60)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure(0.78)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figurenot reported(0.52)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(0.50)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure(0.65)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figurenot reported(0.48)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(0.65)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Basic EPS$ per share(0.36)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.36 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figurenot reported(2.51)Basic EPS, Q1 FY2024, three months to 2024-03-31−$2.51 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure(0.60)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure(0.78)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.78 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figurenot reported(0.52)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(0.50)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.50 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure(0.65)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figurenot reported(0.48)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(0.65)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.65 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure

Balance sheet

Cash and equivalents$217.7m, Q2 FY2026
Shareholders' equity$525.1m, Q2 FY2026
Immunome Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m90.6Cash and equivalents, Q3 FY2023, at 2023-09-30$90.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure98.7Cash and equivalents, FY2023, at 2023-12-31$98.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-19, accession 0001558370-25-003302.Report this figure270Cash and equivalents, Q1 FY2024, at 2024-03-31$269.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure165Cash and equivalents, Q2 FY2024, at 2024-06-30$165.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure156Cash and equivalents, Q3 FY2024, at 2024-09-30$155.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure143Cash and equivalents, FY2024, at 2024-12-31$143.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-03, accession 0001193125-26-088172.Report this figure258Cash and equivalents, Q1 FY2025, at 2025-03-31$257.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure144Cash and equivalents, Q2 FY2025, at 2025-06-30$143.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure273Cash and equivalents, Q3 FY2025, at 2025-09-30$272.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure653Cash and equivalents, FY2025, at 2025-12-31$653.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure583Cash and equivalents, Q1 FY2026, at 2026-03-31$582.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure218Cash and equivalents, Q2 FY2026, at 2026-06-30$217.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Current assets$m91.4Current assets, Q3 FY2023, at 2023-09-30$91.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001558370-23-018425.Report this figure145Current assets, FY2023, at 2023-12-31$144.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-19, accession 0001558370-25-003302.Report this figure313Current assets, Q1 FY2024, at 2024-03-31$313.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-14, accession 0001558370-24-008066.Report this figure284Current assets, Q2 FY2024, at 2024-06-30$284.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011898.Report this figure244Current assets, Q3 FY2024, at 2024-09-30$244.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure221Current assets, FY2024, at 2024-12-31$221.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-03, accession 0001193125-26-088172.Report this figure323Current assets, Q1 FY2025, at 2025-03-31$323.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure277Current assets, Q2 FY2025, at 2025-06-30$277.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure280Current assets, Q3 FY2025, at 2025-09-30$279.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure661Current assets, FY2025, at 2025-12-31$660.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure594Current assets, Q1 FY2026, at 2026-03-31$594.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure538Current assets, Q2 FY2026, at 2026-06-30$538.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Total assets$m93.2Total assets, Q3 FY2023, at 2023-09-30$93.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001558370-23-018425.Report this figure149Total assets, FY2023, at 2023-12-31$148.5m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-19, accession 0001558370-25-003302.Report this figure320Total assets, Q1 FY2024, at 2024-03-31$319.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-14, accession 0001558370-24-008066.Report this figure296Total assets, Q2 FY2024, at 2024-06-30$296.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0001558370-24-011898.Report this figure257Total assets, Q3 FY2024, at 2024-09-30$256.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure240Total assets, FY2024, at 2024-12-31$240.2m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-03, accession 0001193125-26-088172.Report this figure343Total assets, Q1 FY2025, at 2025-03-31$342.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure296Total assets, Q2 FY2025, at 2025-06-30$296.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure299Total assets, Q3 FY2025, at 2025-09-30$299.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure683Total assets, FY2025, at 2025-12-31$683.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure620Total assets, Q1 FY2026, at 2026-03-31$619.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure565Total assets, Q2 FY2026, at 2026-06-30$565.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Current liabilities$m23.1Current liabilities, Q3 FY2023, at 2023-09-30$23.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001558370-23-018425.Report this figure21.8Current liabilities, FY2023, at 2023-12-31$21.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-19, accession 0001558370-25-003302.Report this figure30.8Current liabilities, Q1 FY2024, at 2024-03-31$30.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-14, accession 0001558370-24-008066.Report this figure39.9Current liabilities, Q2 FY2024, at 2024-06-30$39.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0001558370-24-011898.Report this figure39.5Current liabilities, Q3 FY2024, at 2024-09-30$39.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure54.3Current liabilities, FY2024, at 2024-12-31$54.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-03, accession 0001193125-26-088172.Report this figure30.8Current liabilities, Q1 FY2025, at 2025-03-31$30.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure22.9Current liabilities, Q2 FY2025, at 2025-06-30$22.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure31.4Current liabilities, Q3 FY2025, at 2025-09-30$31.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure45.0Current liabilities, FY2025, at 2025-12-31$45.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure27.4Current liabilities, Q1 FY2026, at 2026-03-31$27.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure35.7Current liabilities, Q2 FY2026, at 2026-06-30$35.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Total liabilities$m87.1Total liabilities, Q3 FY2023, at 2023-09-30$87.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001558370-23-018425.Report this figure28.7Total liabilities, FY2023, at 2023-12-31$28.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-19, accession 0001558370-25-003302.Report this figure34.2Total liabilities, Q1 FY2024, at 2024-03-31$34.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-14, accession 0001558370-24-008066.Report this figure42.4Total liabilities, Q2 FY2024, at 2024-06-30$42.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0001558370-24-011898.Report this figure42.0Total liabilities, Q3 FY2024, at 2024-09-30$42.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure59.1Total liabilities, FY2024, at 2024-12-31$59.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-03, accession 0001193125-26-088172.Report this figure35.6Total liabilities, Q1 FY2025, at 2025-03-31$35.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure27.0Total liabilities, Q2 FY2025, at 2025-06-30$27.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure35.5Total liabilities, Q3 FY2025, at 2025-09-30$35.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure48.8Total liabilities, FY2025, at 2025-12-31$48.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure31.1Total liabilities, Q1 FY2026, at 2026-03-31$31.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure40.3Total liabilities, Q2 FY2026, at 2026-06-30$40.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m6.1Shareholders' equity, Q3 FY2023, at 2023-09-30$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure120Shareholders' equity, FY2023, at 2023-12-31$119.9m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-03, accession 0001193125-26-088172.Report this figure286Shareholders' equity, Q1 FY2024, at 2024-03-31$285.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure254Shareholders' equity, Q2 FY2024, at 2024-06-30$253.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure215Shareholders' equity, Q3 FY2024, at 2024-09-30$214.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure181Shareholders' equity, FY2024, at 2024-12-31$181.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure307Shareholders' equity, Q1 FY2025, at 2025-03-31$307.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure269Shareholders' equity, Q2 FY2025, at 2025-06-30$269.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure264Shareholders' equity, Q3 FY2025, at 2025-09-30$263.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure634Shareholders' equity, FY2025, at 2025-12-31$634.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure589Shareholders' equity, Q1 FY2026, at 2026-03-31$588.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure525Shareholders' equity, Q2 FY2026, at 2026-06-30$525.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure

Cash flow

Operating cash flow−$61.7m, Q2 FY2026
Capital expenditure$2.2m, Q2 FY2026
Immunome Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(8.6)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$8.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001558370-24-015524. Derived: 9-month figure less the 6-month figure.Report this figure(17.5)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$17.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-19, accession 0001558370-25-003302. Derived: 12-month figure less the 9-month figure.Report this figure(11.2)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$11.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure(23.4)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$23.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-06, accession 0000950170-25-104035. Derived: 6-month figure less the 3-month figure.Report this figure(34.2)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$34.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269603. Derived: 9-month figure less the 6-month figure.Report this figure(42.1)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$42.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure(53.1)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$53.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(49.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$49.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344636. Derived: 6-month figure less the 3-month figure.Report this figure(40.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$40.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269603. Derived: 9-month figure less the 6-month figure.Report this figure(48.0)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$48.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure(58.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$58.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure(61.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$61.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-11, accession 0001193125-26-344636. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$36.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001558370-24-015524. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2023, three months to 2023-12-31$349.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-19, accession 0001558370-25-003302. Derived: 12-month figure less the 9-month figure.Report this figure2.2Capital expenditure, Q1 FY2024, three months to 2024-03-31$2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure2.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$2.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-06, accession 0000950170-25-104035. Derived: 6-month figure less the 3-month figure.Report this figure1.5Capital expenditure, Q3 FY2024, three months to 2024-09-30$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269603. Derived: 9-month figure less the 6-month figure.Report this figure1.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure3.7Capital expenditure, Q1 FY2025, three months to 2025-03-31$3.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure0.9Capital expenditure, Q2 FY2025, three months to 2025-06-30$905.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344636. Derived: 6-month figure less the 3-month figure.Report this figure1.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269603. Derived: 9-month figure less the 6-month figure.Report this figure4.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$4.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-03, accession 0001193125-26-088172. Derived: 12-month figure less the 9-month figure.Report this figure3.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$3.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure2.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-11, accession 0001193125-26-344636. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)113.27m, Q2 FY2026
Immunome Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares12.1Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3012,127,501 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0001558370-23-018425.Report this figure12.2Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3112,182,478 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-14, accession 0001558370-24-008066.Report this figure12.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3012,197,801 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-12, accession 0001558370-24-011898.Report this figure12.2Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3012,202,335 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001558370-24-015524.Report this figure51.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3151,544,383 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-12, accession 0001558370-25-007382.Report this figure59.9Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3059,936,703 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-06, accession 0000950170-25-104035.Report this figure60.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3060,205,327 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure79.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3179,410,354 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure87.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3087,010,742 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure88.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3087,957,868 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269603.Report this figure113Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31113,136,836 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-12, accession 0001193125-26-219425.Report this figure113Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30113,272,931 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure

Shares outstanding: 113.58mShares outstanding, period not labelled, at 2026-08-06113,577,629 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-11, accession 0001193125-26-344636.Report this figure at Aug 6, 2026, from the cover of the 10-Q filed Aug 11, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. Listed shows no prices and gives no investment advice.